368 related articles for article (PubMed ID: 34913108)
1. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate).
Sattler L; Hanauer SB; Malter L
Curr Gastroenterol Rep; 2021 Dec; 23(12):30. PubMed ID: 34913108
[TBL] [Abstract][Full Text] [Related]
2. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
[TBL] [Abstract][Full Text] [Related]
3. Emerging drugs for the treatment of inflammatory bowel disease.
Wong U; Cross RK
Expert Opin Emerg Drugs; 2022 Dec; 27(4):369-377. PubMed ID: 36369862
[TBL] [Abstract][Full Text] [Related]
4. Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease.
Johnson CM; Dassopoulos T
Curr Gastroenterol Rep; 2018 Sep; 20(11):53. PubMed ID: 30267281
[TBL] [Abstract][Full Text] [Related]
5. Modulation of sphingosine-1-phosphate in inflammatory bowel disease.
Peyrin-Biroulet L; Christopher R; Behan D; Lassen C
Autoimmun Rev; 2017 May; 16(5):495-503. PubMed ID: 28279838
[TBL] [Abstract][Full Text] [Related]
6. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Tennakoon A; Zubieta AA; Coward S; Jones J; Kaplan GG; Kuenzig ME; Murthy SK; Nguyen GC; Peña-Sánchez JN
J Crohns Colitis; 2020 Oct; 14(10):1354-1363. PubMed ID: 32648579
[TBL] [Abstract][Full Text] [Related]
7. Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies.
Katsanos KH; Papamichael K; Feuerstein JD; Christodoulou DK; Cheifetz AS
Clin Immunol; 2019 Sep; 206():9-14. PubMed ID: 29545207
[TBL] [Abstract][Full Text] [Related]
8. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
9. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
[TBL] [Abstract][Full Text] [Related]
10. Indications and safety of newer IBD treatments in the older patient.
Clement B; De Felice K; Afzali A
Curr Gastroenterol Rep; 2023 Jul; 25(7):160-168. PubMed ID: 37227615
[TBL] [Abstract][Full Text] [Related]
11. Novel and Emerging Therapies for Inflammatory Bowel Disease.
Al-Bawardy B; Shivashankar R; Proctor DD
Front Pharmacol; 2021; 12():651415. PubMed ID: 33935763
[TBL] [Abstract][Full Text] [Related]
12. Novel treatments for inflammatory bowel disease.
Lee HS; Park SK; Park DI
Korean J Intern Med; 2018 Jan; 33(1):20-27. PubMed ID: 29223139
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the treatment of IBD: Targets, mechanisms and related therapies.
Liu J; Di B; Xu LL
Cytokine Growth Factor Rev; 2023; 71-72():1-12. PubMed ID: 37455149
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD.
Dulai PS; Siegel CA; Peyrin-Biroulet L
Gastroenterol Clin North Am; 2014 Sep; 43(3):441-56. PubMed ID: 25110252
[TBL] [Abstract][Full Text] [Related]
15. Low-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases.
Borren NZ; Luther J; Colizzo FP; Garber JG; Khalili H; Ananthakrishnan AN
J Crohns Colitis; 2019 Aug; 13(8):990-995. PubMed ID: 30888405
[TBL] [Abstract][Full Text] [Related]
16. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
Peyrin-Biroulet L; Rahier JF; Kirchgesner J; Abitbol V; Shaji S; Armuzzi A; Karmiris K; Gisbert JP; Bossuyt P; Helwig U; Burisch J; Yanai H; Doherty GA; Magro F; Molnar T; Löwenberg M; Halfvarson J; Zagorowicz E; Rousseau H; Baumann C; Baert F; Beaugerie L;
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):771-788.e10. PubMed ID: 36152897
[TBL] [Abstract][Full Text] [Related]
17. Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy.
Pratt PK; David N; Weber HC; Little FF; Kourkoumpetis T; Patts GJ; Weinberg J; Farraye FA
Inflamm Bowel Dis; 2018 Jan; 24(2):380-386. PubMed ID: 29361083
[TBL] [Abstract][Full Text] [Related]
18. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
19. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
